Synergy CHC Files Chapter 11; Board Collapses to a Single Director
SNYR is trading near its 52-week low of $0.082 (6.0% above the low) on light trading volume (0.1× avg).
Summary
Synergy CHC Corp. filed a voluntary Chapter 11 bankruptcy petition on September 4, 2026, and four directors resigned the same day, leaving a single-member board. The company anticipates filing a liquidation or reorganization plan within 120 days.
Key Events · Legal and Risk Events · SNYR
-
Chapter 11 Bankruptcy Filed
Synergy CHC Corp. filed a voluntary Chapter 11 petition on September 4, 2026 in the U.S. Bankruptcy Court for the District of Columbia (Case No. 26-465-ELG), operating as a debtor-in-possession.
-
Liquidation or Reorganization Plan Expected
The company anticipates filing a plan of liquidation or reorganization within the forthcoming 120-day period, with a creditors' meeting to be scheduled per Bankruptcy Code requirements.
-
Board Collapses to Single Director
Four directors — Alfred Baumeler, Nitin Kaushal, J. Paul SoRelle, and Teresa Thompson — resigned effective September 4, 2026, leaving Jack Ross as the sole board member. Baumeler also resigned as President effective August 31, 2026.
-
Chief Restructuring Officer Appointed
Lauren P. Berret of Eisner Advisory Group LLC was engaged as chief restructuring officer effective August 26, 2026, and The VerStandig Law Firm was retained as bankruptcy counsel.
Analysis · SNYR · Life Sciences
Synergy CHC Corp. filed for Chapter 11 bankruptcy protection on September 4, 2026, after weeks of escalating distress — a defaulted $17.6M term loan, lender acceleration of the full $18.9M balance, a Nasdaq delisting notice, and the loss of its Costco FOCUSfactor business. The company now operates as a debtor-in-possession and expects to file a liquidation or reorganization plan within 120 days. Simultaneously, four of five directors resigned, leaving Jack Ross as the sole board member, and the company brought in a chief restructuring officer. For shareholders, this filing confirms the company's descent into formal insolvency proceedings, where equity is typically wiped out or severely impaired in a liquidation scenario.
At the time of this filing, SNYR was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.08 to $2.96. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.